The regulatory greenlight for Phase 2/3 initiation is the primary catalyst — watch for actual trial commencement in Q2 2026 and any additional financing needs given the $2.4M cash position. The stock is likely to trade on clinical milestones rather than financial results; monitor for enrollment updates and potential partnership interest.
Price Chart
Executive Summary
Silexion Therapeutics reported Q1 2026 financial results, highlighting a net loss of $2.7M (vs $1.7M in Q1 2025) and cash burn to $2.4M from $6.0M at year-end 2025. The key catalyst is the Israeli Ministry of Health approval to initiate a Phase 2/3 trial of SIL204 in pancreatic cancer, with a CTA submitted to Germany and trial initiation on track for Q2 2026. The company also raised ~$1.0M post-quarter via a warrant exercise inducement to restore Nasdaq equity compliance.
Key Financial Metrics
Key Facts
- Israeli Ministry of Health approved Phase 2/3 trial initiation of SIL204 in locally advanced pancreatic cancer on March 24, 2026
- Clinical Trial Application submitted to Germany via EU CTIS on April 28, 2026
- Phase 2/3 trial initiation remains on track for Q2 2026 with ~18-patient safety run-in and ~166-patient randomized cohort
- Net loss for Q1 2026 was approximately $2.7 million, up 58.8% from $1.7 million in Q1 2025
- Cash and cash equivalents were $2.4 million as of March 31, 2026, down from $6.0 million at December 31, 2025
- Post-quarter warrant exercise inducement generated approximately $1.0 million in gross proceeds, restoring Nasdaq shareholders' equity compliance above $2.5 million minimum
Financial Impact
Net loss increased 58.8% to $2.7M; cash burn of $3.6M in Q1; post-quarter equity raise of ~$1.0M
Risk Factors
- Cash runway is limited — $2.4M may not sustain operations through the Phase 2/3 trial without additional financing
- Clinical trial risk — SIL204 has not been tested in humans; safety/efficacy data is unknown
- Nasdaq compliance remains fragile — shareholders' equity was only recently restored above $2.5M minimum
- Dilution risk from continued at-the-market offerings and warrant exercises
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001178913-26-002761 |
| Document: zk2635360.htm | 0001178913-26-002761 |
| Document: 0001178913-26-002761-index-headers.html | 0001178913-26-002761 |
| Document: 0001178913-26-002761-index.html | 0001178913-26-002761 |
| Document: 0001178913-26-002761.txt | 0001178913-26-002761 |
| 8-K Data (Synthetic) | 0001178913-26-002761 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
May 29, 2026 21w ago | 8-K | $0.0334 | awaiting T+60 | — | — |
May 26, 2026 22w ago | 8-K | $0.0334 $0.0184 | ▼ −44.91% | ▼ −47.63% | — |
May 18, 2026 23w ago | 8-K | $0.0334 $0.0130 | ▼ −61.08% | ▼ −65.93% | — |
May 15, 2026 23w ago | 8-K | $0.0334 $0.0130 | ▲ +61.08% | ▲ +65.93% | — |
May 13, 2026 23w ago | 8-K | $0.0334 | awaiting T+60 | — | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers